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Abstract 
Since its characterization two decades ago, the phosphatase PHOSPHO1 has been the subject 
of an increasing focus of research. This work has elucidated PHOSPHO1’s central role in the 
biomineralization of bone and other hard tissues, but has also implicated the enzyme in other 
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biological processes in health and disease. During mineralization PHOSPHO1 liberates 
inorganic phosphate (Pi) to be incorporated into the mineral phase through hydrolysis of its 
substrates phosphocholine (PCho) and phosphoethanolamine (PEA). Localization of 
PHOSPHO1 within matrix vesicles allows accumulation of Pi within a protected environment 
where mineral crystals may nucleate and subsequently invade the organic collagenous 
scaffold. Here, we examine the evidence for this process, first discussing the discovery and 
characterization of PHOSPHO1, before considering experimental evidence for its canonical 
role in matrix vesicle-mediated biomineralization. We also contemplate roles for PHOSPHO1 
in disorders of dysregulated mineralization such as vascular calcification, along with 
emerging evidence of its activity in other systems including choline synthesis and 
homeostasis, and energy metabolism. 
Keywords: PHOSPHO1, phosphocholine, inorganic phosphate, biomineralization, matrix 
vesicle 
1. Introduction 
Biomineralization of the skeleton is a fundamental process indispensable for health and 
wellbeing throughout life. The vertebrate skeleton is a complex organ which performs varied 
and diverse functions encompassing its action as a biomechanical and protective scaffold in 
conjunction with the musculature, its role in calcium and phosphate ion homeostasis, and 
recent evidence demonstrating its capacity as an endocrine organ involved with energy 
homeostasis(1). At the level of molecular constituents bone is composed of a combination of 
inorganic mineral, Type I collagen, non-collagenous proteins (NCPs) and water, arranged 
into an extremely ordered hierarchical structure(2). The fine details of this architecture remain 
controversial at the nanostructural level(3), particularly with respect to differences between 
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embryonic and mature tissue, however the mineral phase has come to be regarded as a 
poorly-crystalline substituted hydroxyapatite phase, mainly composed of calcium phosphate. 
Biomineralization of the skeleton therefore requires generation and manipulation of calcium 
and phosphate ions on a massive scale. The biological mechanisms through which ions are 
liberated, contained, and targeted to the developing collagenous framework, and ultimately 
nucleate mineral in a controlled manner, remain the subject of intense research. Phosphatase 
enzymes are essential in promoting biomineralization as one pathway through which 
inorganic phosphate (Pi) may be liberated from biological molecules. These include enzymes 
with a canonical role in bone development such as tissue non-specific alkaline phosphatase 
(TNAP). While TNAP activity has long been implicated in the mineralization process, it is 
now recognized that TNAP is only one component and the full story requires a more complex 
biochemical system. 
Orphan phosphatase 1 (PHOSPHO1; EC 3.1.3.75; encoded by the Phospho1 gene in the 
mouse and the PHOSPHO1 gene in humans) has been an increasing focus of research in this 
field over the last 20 years and now holds an established function in biomineralization. Here 
we review the scientific literature on the characterization, localization, regulation and activity 
of PHOSPHO1 with respect to its role in physiological and pathological biomineralization, 
along with potential contributions to other biological processes. 
2. Characterization, protein structure and substrate specificity 
PHOSPHO1 (originally known as 3X11A) was initially cloned from chick hypertrophic 
growth plate chondrocytes, in which a 5-fold increase in expression was observed in 
comparison to resting or proliferative chondrocytes(4). This distinct upregulation was also 
found be approximately 100-fold higher than in non-chondrogenic tissues. Although the 
specific function of this novel protein was at this stage unknown, sequencing of the 3X11A 
  
4 
 
RNA transcript derived from differential display analysis revealed two partially conserved 
domains which bore sequence similarity to the phosphotransferase enzyme superfamily, 
including the ATPases and various phosphatases catalysing Pi liberation from a range of 
phosphomonoester substrates(4). Primers designed against these motifs succeeded in 
transcribing a 537bp fragment from RNA isolated from the human osteosarcoma SaOS-2 cell 
line, demonstrating 69% similarity to the chicken sequence(5). These fragments were 
identified as corresponding to several previously unattributed EST transcripts from both the 
human and mouse Phospho1 gene, with a high degree of conservation at both the gene and 
protein level between these two mammalian species. Chromosomal mapping led to the 
conclusion that the Phospho1 gene was indeed conserved between the bird and mouse 
genomes, located within a region of conserved synteny on the HSA17 and GGA27 
chromosomes respectively(5). 
Stewart et al used homology modelling to identify three conserved peptide motifs composing 
the active site; certifying PHOSPHO1’s membership of the Mg2+-dependent haloacid 
dehalogenase (HAD) superfamily(6). These included two characteristic aspartic acid residues 
in motif 1 which co-ordinate the catalytic Mg2+ ion in this family, along with other markers 
such as the hydrophobic amino acid residues within motif 2. Along with identification of 
orthology between PHOSPHO1 in rat and the previously identified species, substantial 
homology between the amino acid sequences of PHOSPHO1 and proteins in the fruit fly was 
also found, along with several plant species including the LePS2 phosphatases in the tomato 
plant involved with phosphate homeostasis(7-9). 
A PHOSPHO1 model protein structure was developed, based upon the crystal structure of the 
phosphoserine phosphatases (PSPs)(6,10). This model revealed conservation of residues 
complexing the substrate phosphate group, however those residues which confer substrate 
specificity to phosphoserine in the PSPs are absent. Roberts et al purified recombinant human 
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PHOSPHO1 by amplification of a curtailed cDNA transcript from the SaOS-2 osteosarcoma 
cell line and continuous spectrophotometric phosphate assays with several potential 
phosphomonoester substrates revealed PHOSPHO1’s specific activity towards the 
metabolites phosphoethanolamine (PEA) and phosphocholine (PCho), with highest activity 
between pH6.0-7.2(11). Disruption of the protein active site using site-directed mutagenesis 
decreased PEA and PCho hydrolysis dramatically to an undetectable level in some 
mutants(12). 
3. Bone biology and mineralization 
The ubiquitous phosphatase TNAP has a long-established role during skeletal 
biomineralization. Mutations in the ALPL gene are associated with several skeletal disorders 
in humans including various forms of hypophosphatasia(13-15). Genetic ablation of TNAP in a 
mouse model induced a phenotype mimicking infantile hypophosphatasia with severe skeletal 
abnormalities(16,17), including those in dental and craniofacial mineralization and 
morphology(18,19). Detailed ultrastructural examination of these mice revealed that although 
hypomineralization of the skeleton was evident, hydroxyapatite mineral crystals were 
generated as normal(20). The hypomineralized phenotype was therefore attributed to the 
inability of the mineral phase to propagate in the absence of TNAP’s hydrolysis of the potent 
mineralization inhibitor pyrophosphate (PPi)
(20,21). 
These observations led to the hypothesis that another phosphatase was active during skeletal 
biomineralization with PHOSPHO1 a strong candidate to fulfil this role. Following the 
observation of PHOSPHO1 upregulation in mineralizing hypertrophic chondrocytes(4), 
immunohistochemistry revealed localization of the protein to these cells in the chick growth 
plate, along with active bone surfaces at the ossification front and in the trabecular 
compartment(22). Whole-mount in situ hybridization in the embryonic chick lower limb 
  
6 
 
furthermore demonstrated expression of PHOSPHO1 restricted to the developing bones 
during ossification(23). In vivo suppression of PHOSPHO1 activity using the non-competitive 
inhibitor lansoprazole (identified specifically as an inhibitor of PHOSPHO1(24)) during chick 
development induced ablation of mineralization in the lower limb bones(23). Together these 
data provided strong evidence that this novel phosphatase plays a critical role in the very first 
steps of skeletal biomineralization. 
The generation of the PHOSPHO1 knock-out mouse (Phospho1-/-) enabled the detailed 
investigation of its phenotype and thereby allowed interrogation of the enzyme’s specific 
function in the skeleton(25). Huesa et al used a variety of compositional and biomechanical 
analyses to show that the mineral:matrix ratio of femora of juvenile Phospho1-/- mice was 
significantly lower than wild-type controls, accompanied by plastic deformation upon 3-point 
bending and a reduced hardness and elastic modulus(26). A further investigation of the 
mechanical properties of these bones corroborated this high fracture toughness and also 
showed significantly higher indentation distance increases under reference point indentation 
compared to wild-type controls(27). Histological examination of Phospho1-/- long bones 
revealed reduced mineralization in the trabecular compartment, while 10-15% of 10-day old 
mice exhibited a complete lack of secondary ossification centre development(25). These bones 
also demonstrated osteoid accumulation; a hallmark of hypophosphatasia (Figure 1). 
Interestingly, micro-computed tomography (µCT) revealed no differences between 4-week 
Phospho1-/- and wild-type mice in bone volume relative to tissue volume (BV/TV), but rather 
a significantly reduced bone mineral density (BMD) which was accompanied by diverse 
spontaneous greenstick fractures and marked thoracic scoliosis(25) (Figure 1). Similarly, 
PHOSPHO1 plays a critical role in fracture healing, with induced tibial fractures in 
Phospho1-/- mice demonstrating osteoid accumulation and elastic deformation upon loading 
after four weeks post-surgery(28). 
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These findings have been extended to investigate the function of PHOSPHO1 in the 
development of bone’s hydroxyapatite mineral phase at the smallest length scales. X-ray 
diffraction (XRD) along with thermogravimetric analysis (TGA) revealed a lower bulk 
mineral content with significantly lower mineral:matrix ratio in Phospho1-/- femora, also 
accompanied by a smaller apatite crystal size(29). Backscattered scanning electron microscopy 
(BSE-SEM) furthermore revealed generalized hypomineralization relative to wild-type mice 
in transverse tibial cross-sections of the same animals(29). Further analysis of the Phospho1-/- 
microstructure exposed diffuse regions of hypomineralization in diaphyseal cortical and 
trabecular bone with large areas of osteoid accumulation(30). Interestingly, there was no 
discernible anatomical pattern between individual Phospho1-/- animals, but regions lacking 
mineral exhibited small focal areas of mineral nucleation at their borders, which failed to 
propagate more widely. 
In the very early studies of its function, characterization of the Phospho1-/- bone phenotype 
was performed in young juvenile mice, and therefore to examine the bone phenotype more 
fully Javaheri and colleagues investigated whether PHOSPHO1 plays a persistent long-term 
role in the adult bone’s biology where skeletal turnover is relatively slow(31). Using digital 
image correlation (DIC) the expected lower stiffness of Phospho1-/- was found, which was 
corrected with age. µCT analysis demonstrated several differences in tibial trabecular 
microarchitecture, including trabecular number and connectivity, between Phospho1-/- and 
wild-type mice which changed transiently across four age groups, with significant differences 
detected in the 5- and 34-week age groups, but not in the 7- or 16-week groups. Upon 
examination of the cortical bone however, the authors noted a significant reduction in BV/TV 
in animals from 7 weeks of age which was not corrected over time. NanoCT scanning (0.6µm 
resolution) furthermore revealed a greater number of larger osteocyte lacunae, along with 
higher vascular porosity in Phospho1-/- tibiae; a surprising finding which was compounded by 
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an early increase in both Pdpn (E11) mRNA expression in primary osteoblast cell cultures, 
potentially indicating accelerated terminal osteocyte differentiation in these cells(31). 
PHOSPHO1 may therefore play a role in regulation of osteocytogenesis, which in turn may 
regulate bone microarchitecture in skeletally mature animals. Further research is required 
however to assess whether this relationship is mediated through reduced mineralization, or 
whether PHOSPHO1 may act within a distinct mechanism altogether. Our data also shows 
that the Phospho1-/- phenotype is present during skeletal development, with murine embryos 
exhibiting a reduced extent of mineralization across all bones during embryogenesis 
(unpublished data; Figure 2). 
Aged 1-year old Phospho1-/- mice showed reduced plasma concentrations of TNAP with a 
concomitant increase in ectonucleotide pyrophosphatase/phosphodiesterase1 (NPP1), thereby 
resulting in significantly higher PPi concentrations compared with wild-type controls
(25). 
Intriguingly, high serum PPi is a key characteristic of infantile hypophosphatasia in humans, 
with the resulting inhibition of mineralization attributed to the ensuing 
rickets/osteomalacia(17,32). Yadav et al attempted to rescue the Phospho1-/- phenotype by 
cross-breeding with mice over-expressing TNAP (ApoE-Tnap) and thereby reduce PPi 
concentration(25). While the authors did indeed observe a ~4-fold increase in TNAP in plasma 
and a significant reduction in PPi, the hypomineralized Phospho1
-/- phenotype was not 
corrected, with animals exhibiting persistent skeletal defects at 7-months. Furthermore 
PHOSHO1; TNAP double knock-out (Phospho1-/-; Alpl-/-) mice exhibited complete ablation 
of skeletal mineralization and perinatal lethality(25). These data were augmented and 
confirmed in vitro with osteoblast-like MC3T3-E1 cell lines (clones 14 and 24) along with ex 
vivo metatarsal cultures using specific PHOSPHO1 and TNAP inhibitors in culture(33). 
PPi is known to regulate the expression of other mineralization-associated proteins, 
particularly osteopontin (OPN; Spp1)(34-36). Along with PPi, OPN is another potent 
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mineralization inhibitor(37-39). The protein’s inhibitory effects are mediated through its 
phosphorylation status(40,41) and this has been shown to be regulated by TNAP(42). 
Significantly elevated OPN, which also exhibited a greater degree of phosphorylation 
compared to controls, was found at the protein and gene levels in serum and spinal lysates of 
Phospho1-/- mice at 1- and 3-months postnatal(43). Interestingly, no differences were observed 
in femoral lysates. Yadav et al investigated the interplay between PHOSPHO1 and OPN 
through the generation of Phospho1-/-; Spp1-/- mice and found a partial rescue of the 
Phospho1-/- phenotype, with animals at 1- and 3-months of age exhibiting a reduction in the 
typical hyperosteoidosis and thoracic scoliosis which characterises the single knock-out 
animal(43). The Phospho1-/- hypomineralized mouse phenotype is therefore partially 
attributable to an increased expression of OPN which may obstruct mineralization during 
bone formation. This is likely exacerbated by a relative hyperphosphorylation of OPN, 
mediated by the established reduced expression of Alpl in Phospho1-/- mice(25,43). 
Collectively these findings establish a non-redundant role of PHOSPHO1 in mediating 
biomineralization of the skeleton, as well as its regulated synergy with TNAP, along with 
other mineralization-associated factors including PPi and OPN, as part of this process. 
4. Dental mineralization 
Along with its established role in bone biomineralization, PHOSPHO1 has also been 
implicated in the mineralization process of the dentition. McKee et al studied dentin 
formation in perinatal mice and found localization of PHOSPHO1 to odontoblasts during the 
very first steps of dentin formation(44). Phospho1-/- mice exhibited reduced mineralization in 
the dentin by histology, µCT and radiography; a phenotype which was aggravated by the 
additional deletion of one Alpl allele (Phospho1-/-; Alpl+/-). Others have examined 
PHOSPHO1 function in the other dental hard tissues, namely cementum and enamel. 
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PHOSPHO1 was found to show expression in osteoblasts and cementoblasts of alveolar bone 
and cementum respectively during their mineralization phases where osteoid accumulation 
was evident in the bone and was accompanied by delayed mineralization of the cellular 
cementum in Phospho1-/- animals(45). Intriguingly, acellular cementum formation was normal, 
despite downregulation of Phospho1-/- in a bone sialoprotein knock-out model in this 
region(46). PHOSPHO1 is therefore an enzyme critical for the integrity of the periodontal 
tissue interface, along with normal development of these hard tissues. In enamel, Phospho1-/- 
mice exhibited a 25% increase in tissue volume, with a significantly reduced level of 
mineralization(47). The authors furthermore reported that ablation of PHOSPHO1 caused loss 
of enamel prism morphology and an impaired crystal organization compared to wild-type 
mice. 
At the level of local cellular regulation, control of mineralization through the PHOSPHO1 
pathway has been shown to be influenced by the TRPS1 transcription factor in an 
odontoblast-like cell line(48). Mutations in the Trps1 gene are associated with tricho-rhino-
phalangeal syndrome in humans and manifest craniofacial and skeletal dysplasias associated 
with defective endochondral mineralization(49-51). Loss of TRPS1 has also been implicated in 
abnormal tooth development and mineralization(52). Kuzynski and colleagues overexpressed 
Trps1 in preodontoblastic 17IIA11 cells and found reduced mineralization compared with 
controls(48). Interestingly reduction of Trps1 expression also ablated mineralization and was 
associated with downregulation of Phospho1 and Alpl expression. The authors proposed that 
TRPS1 acts to repress mineralization associated genes in dentin in a biphasic manner to first 
inhibit ectopic mineralization, and further to prevent hypermineralization by modulation of 
osteogenic gene expression, including Phospho1. 
5. The PHOSPHO1 mineralization mechanism: matrix vesicle-mediated 
biomineralization 
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Matrix vesicles (MVs) are membrane-bound nano-spherical bodies of approximately 100-
300nm in diameter which are typically rich in lipids and proteins known to chelate Ca2+ and 
Pi, and which are associated with both physiological and pathological biomineralization
(53). 
Their function continues to be remain controversial since their discovery in 1967 in growth 
plate cartilage(54,55), with some authors attributing these as specimen preparation artefacts(56). 
Nevertheless, many in vitro and in vivo studies have shown the first mineral crystals in 
diverse mineralized tissues such as bone, dentin, cartilage and mineralized vasculature are 
associated with these structures in the extracellular matrix (ECM)(55,57-63). 
The structure and function of MVs in skeletal and vascular mineralization has recently been 
reviewed by several authors(53,64-67). The biogenesis of these vesicles may occur through 
multiple proposed mechanisms, however the most prevalent theories include polarized 
budding from the parental cell membrane, or from microvilli on the cell surface, as 
demonstrated in hypertrophic chondrocytes and SaOS-2 osteoblast-like cells(68-71). The 
theorized function of MVs in biomineralization is to facilitate a localized concentration of 
Ca2+ and Pi, protected from the ECM, from which hydroxyapatite or its precursors may 
form(53). Vesicles may also assist in concentrating Pi to engender a Pi:PPi ratio which is 
permissible for mineralization(72). MVs are known to be enriched in Ca2+ by way of their 
intracellular biogenesis from mitochondria under oxidative stress, at least in growth-plate 
chondrocytes(73,74). Recently published research by Chaudhary and colleagues may correlate 
well with these findings, showing that Pi stimulates release of MVs from osteogenic cells, 
although the authors did not comment on their mitochondrial origin(75). 
Pi accumulation within MVs is thought to be mediated by extra- and intravesicular 
phosphatases, of which PHOSPHO1 plays a critical role(11,20,25,26,76-78). Stewart and colleagues 
were the first to suggest PHOSPHO1 as a major intravesicular phosphatase, showing its 
presence in MVs isolated from embryonic chick growth plates(77). This was more recently 
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confirmed in MVs isolated from the ECM of both cultured MC3T3 and SaOS-2 osteoblast-
like cells using Western blotting(75) and quantitative proteomics(71,79). Further work using both 
growth plate- and primary osteoblast-derived vesicles established that while TNAP does 
indeed liberate Pi extravesicularly, PHOSPHO1 is biochemically active intravesicularly
(24,80). 
Therefore it is hypothesized that accumulation of Pi inside MVs occurs via a combination of 
the intravesicular action of PHOSPHO1 and intravesicular trafficking of TNAP-generated Pi 
via a Type III Na-Pi co-transporter, PiT1 (encoded by the Slc20a1 gene in mice)
(77,80) (Figure 
3). Experimental evidence for this hypothesis comes from the work of Yadav and colleagues 
who generated a cartilage specific PiT1 knock-out mouse driven by a col2a1-Cre on a 
Phospho1-null background (Phospho1-/-; PiT1
Col2/Col2)(81). The authors report an exacerbation 
of the Phospho1-/- phenotype, including growth plate defects, extensive hyperosteoidosis, 
decreased BMD and impaired mechanical properties. MVs isolated from differentiating 
chondrocytes in these animals furthermore demonstrated a loss of their capacity to nucleate 
hydroxyapatite crystals compared to both Phospho1-/- and wild-type controls(81). Interestingly, 
both Phospho1-/- and Phospho1-/-; PiT1
Col2/Col2 MV were reduced in numbers compared to 
wild-types, potentially indicating a role for PHOSPHO1 in MV biogenesis. Together these 
studies, along with those characterising the Alpl-/- and Phospho1-/-; Alpl-/- mice(16,17,20,21,25), 
afford good evidence for this mechanism integrating the PHOSPHO1 and TNAP Pi 
generation pathways. 
While this work provides a strong evidence base for the pivotal role of PHOSPHO1 in 
vesicle-mediated biomineralization, the specific biochemical pathway within which it 
achieves intravesicular Pi liberation remains unclear. Stewart et al proposed a mechanism 
through which PHOSPHO1’s substrates PEA and PCho may be generated intravesicuarly by 
enzymatic action upon the vesicle’s phospholipid membrane, as mediated by a phospholipase 
A2 (PLA2) and ectonucleotide pyrophosphatase/phosphodiesterase 6 (NPP6)
(82) (Figure 3). 
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The PLA2 family of enzymes catalyse cleavage of the acyl group at the sn-2 acyl position of 
glycerophospholipids resulting in a free fatty acid and lysophospholipid (LPL)(83-85). These 
enzymes may therefore act to breakdown phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) in the MV membrane, forming 
lysophosphatidylethanolamine and lysophosphocholine LPLs respectively along with 
arachidonic acid(82). Indeed the MV membrane has been shown to be enriched in 
phospholipids containing PCho and PEA which progressively decline during 
mineralization(74,86,87), while PCho was also identified as an abundant metabolite in 
developing mouse long bones by matrix-assisted laser desorption/ionization-imaging mass 
spectrometry(88). There are upwards of 30 identified mammalian PLA2 enzymes which exhibit 
a huge range of localizations (including secreted, cytosolic and lysosomal groups) and have 
been shown to be involved with many physiological and pathological processes(83-85). 
Mebarek and colleagues comprehensively reviewed the evidence for the role of 
phospholipases in mineralization, noting several experimental studies confirming expression 
of both secreted and cytosolic PLA2s in chondrocytes and osteoblasts where they play several 
roles(89). While some specific PLA2s have been shown to have an effect on bone formation
(90) 
it is currently unclear whether these act directly within the mineralization process. Further 
research is required therefore to identify specific candidate proteins which fulfil this niche. 
A second enzymatic processing phase is hypothesized to convert generated LPL to PCho for 
direct hydrolysis by PHOSPHO1, mediated by NPP6(82). NPP6 is a member of the nucleotide 
pyrophosphatase/phosphodiesterase family and has been shown to possess lysophospholipase 
C activity, catalysing the conversion of lysophosphocholine with a monoacylglycerol by-
product(91-93). Expression of NPP6 has been demonstrated in bone tissue lysate and was 
immunolocalized to hypertrophic chondrocytes and forming bone surfaces(82). Specific 
localization of NPP6 to MVs has yet to be established however. 
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Alternative biochemical pathways through which PHOSPHO1 substrates may be generated 
have also been proposed (Figure 3). Neutral sphingomyelinase 2 (nSmase2) is encoded by the 
Smpd3 gene in mice and is capable of catalysing the hydrolysis of another MV membrane 
phospholipid sphingomyelin, to produce PCho with a ceramide by-product(94). The fro 
mutation in the Smpd3 gene generates a distinctive phenotype with extensive musculoskeletal 
defects resulting in dwarfism(95,96). Khavandgar and colleagues demonstrated that the fro/fro 
mouse exhibits delayed mineralization of the long bones and calvaria, along with impaired 
hypertrophy in growth plate chondrocytes during embryonic development(97). Using tissue-
specific mouse knock-out models it was also established that Smpd3 expression is required in 
both osteoblasts and chondrocytes in a cell-autonomous manner for normal bone 
development(97,98). These effects were moreover shown to influence mineralization during 
tooth development and fracture healing(99,100). Like PC and PE, sphingomyelin is enriched in 
MV preparations and declines during mineralization(74,86,87), while the nSmase2 enzyme has 
been localized to MV isolates in conjunction with PHOSPHO1(79). nSmase2-mediated 
production of PCho may therefore provide another pathway for the intravesicular generation 
of PHOSPHO1 substrates. Another potential alternative pathway includes generation of PCho 
by phosphorylation of choline through the action of the α and β choline kinases (encoded by 
the Chkα and Chkβ genes respectively). While mice lacking Chkα display lethality during 
embryonic development(101), the Chkβ-/- mouse exhibits forelimb deformaties and delayed 
mineralization, accompanied by an extended and disorganized hypertrophic zone within the 
growth plates at the distal radius and ulna(102). PCho was also shown to be reduced by ~75% 
in primary chondrocytes isolated from these animals(102). Intriguingly, PHOSPHO1 was 
upregulated in Chkβ-/- primary chondrocytes, potentially indicating compensation for a 
restricted substrate availability(102). Both Chkα and Chkβ were found to be expressed in 
human osteoblast-like MG-63 cells, and gene silencing of Chkα resulted in a reduction of 
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~70% in cellular PCho with an accompanied inhibition of TNAP activity and mineralization 
in culture(103). 
6. Endocrinology and regulation 
As a critical effector of biomineralization it is likely that PHOSPHO1 expression and 
function will be stringently controlled at both the local and systemic level. As a major organ, 
and one which is metabolically expensive to produce and maintain, it is well established that 
bone formation and resorption are tightly controlled by many factors during development and 
in adulthood, some of the most significant of which include the sex steroids(104-106), vitamin 
D(107-109) and parathyroid hormone (PTH)(110-112). Whether the observed differences in 
mineralization caused by regulatory influences are caused wholly or partly by control of 
PHOSPHO1 or other associated proteins is as yet unknown. 
Some evidence for the systemic regulation of PHOSPHO1 comes from work surrounding the 
effect of PTH on osteoblasts, with RNA-seq in an osteocyte-like cell line (IDG-SW3 cells) 
stimulated with PTH in culture demonstrated an effect on both Phospho1 and Smpd3 
expression(113). Houston et al extended these analyses, examining the expression of 
Phospho1, Smpd3 and Alpl specifically in a MC3T3 osteoblast-like cells and ex vivo calvaria 
culture models with continuous PTH exposure(114). The authors report rapid and co-ordinate 
downregulation of Phospho1 and Smpd3 expression after the addition of PTH to culture 
media, which was likely regulated through the cAMP/PKA signalling pathway. This 
downregulation of both Phospho1 and Smpd3 was independently found in Kusa 4b10 cells 
and in young rats exposed to PTH and PTH-related protein 1 (PTHrP)(115,116). The catabolic 
effects of continuous PTH on the skeleton are well demonstrated in human conditions such as 
hyperparathyroidism, however much research has associated this with the upregulation of 
osteoclastogenesis through the RANKL/OPG axis(117-119). These data may indicate however a 
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simultaneous mechanism effecting inhibition of bone formation as mediated by PHOSPHO1.  
The transcription and post-translational modification (phosphorylation) of Runx2, the 
transcription factor and master regulator of osteoblast differentiation, is also strongly 
enhanced by PTH(120). Interestingly, the overexpression of Runx2 in mouse limb bud cultures 
simultaneously enhances the expression of both Phospho1 and Smpd3(121). 
Collectively these data surrounding PTH tentatively suggest that control of bone 
biomineralization may occur by modulating PHOSPHO1 expression, and thereby the MV-
mediated biomineralization mechanism. This relationship is however currently far from 
explicit and much further research is required to establish the regulatory mechanisms behind 
PHOSPHO1 expression and function within the context of the MV. 
7. PHOSPHO1 in pathologies of mineralization 
Aside from its central function in mediating physiological biomineralization, PHOSPHO1 
may also have a role to play in the onset of pathological mineral formation, for example in 
vascular calcification. Phospho1 is upregulated during mineralization of vascular smooth 
muscle cells (VMSCs) in culture, while Phospho1-/- VSMCs exhibited a significant reduction 
in mineral generation(122). Also, the PHOSPHO1 inhibitor, MLS-0263839 reduced 
calcification of cultured VSMCs by ~60% and when combined with the TNAP inhibitor 
MLS-0038949, calcification of VSMCs was reduced by ~80%(122). Phospho1 is also 
upregulated during atherosclerotic vascular calcification in a rabbit model(123). Furthermore, 
Hortells et al induced aortic calcification in a rat nephrectomy model with a 1.2% 
phosphorous diet for 12 weeks post-surgery and observed significant upregulation of 
Phospho1 expression in animals exhibiting calcification, along with several other 
mineralization-associated genes(124). These studies suggest that PHOSPHO1 has a critical role 
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in VSMC mineralization and that ‘‘phosphatase inhibition’’ may offer therapeutic strategies 
to mitigate vascular calcification. 
Several authors have investigated the process responsible for vascular calcification, with 
some implicating PHOSPHO1 and TNAP as part of the MV mechanism(125,126). Scanning 
electron microscopy (SEM) and focussed ion beam scanning electron microscopy (FIB-SEM) 
of human calcified valves and vasculature revealed nanospherical particles composed of 
crystalline calcium phosphate(127). Using in vitro models together with calcified human tissue, 
these particles were later implicated in the formation of mineralized atherosclerotic plaques 
through their initial aggregation and nucleation of the mineral phase(128). Furthermore, 
particles isolated from mineralized aortae were subsequently shown to induce pathological 
changes in valvular endothelial cells (VECs) and valvular interstitial cells (VICs) in 
culture(129). These studies demonstrate compelling similarities between calcified particles 
found in the vasculature and MVs. The localization of PHOSPHO1 or other MV-associated 
enzymes with these structures has not as yet however been confirmed and so the mechanism 
behind their generation remains elusive. 
There is now substantial evidence that the mineralization status of the subchondral bone is 
altered in osteoarthritis, and that this may lead to modified mechanical integrity, engendering 
greater articular cartilage degeneration(130). Phospho1 is upregulated during chondrocyte 
differentiation(131), and aged hypomineralized Phospho1-/- mice exhibit increased articular 
cartilage degradation and osteophyte formation, when compared to the age-matched wild-
type mice(132). Further, non-invasive loading of Phospho1-/- mouse knee joints revealed 
diminished loading-induced changes in the subchondral bone plate thickness and epiphyseal 
trabecular bone microarchitecture(132). Together, these data suggest that the hypomineralized 
bone phenotype in Phospho1-/- mice provokes osteoarthritis pathology. This therefore implies 
that local modifications in the bone matrix mineralization may underpin subchondral bone 
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sclerosis in osteoarthritis, however further analyses are required to fully define this 
relationship. 
There are also more speculative roles for PHOSPHO1 in osteoarthritis due to its role as a 
phosphatase capable of hydrolysing PCho and PEA. Lipidomic analysis of the synovial fluid 
from patients with osteoarthritis suggests that alterations in the phospholipid composition and 
concentrations are associated with disease development, due to the lubricating function of the 
synovial fluid in the joint(133). Specifically, PC concentrations are increased in the synovial 
fluid of both early (2.7-fold) and late (5.4-fold) osteoarthritic patients in comparison to 
controls(133). Similarly, there has been reported high activity of PLA2, thought to breakdown 
PC, in the synovial fluid of osteoarthritic patients(134) and a role for PLA2, in articular 
cartilage chondrocyte function(135). It has been suggested that the ratio of PC to 
lysophosphatidylcholine is a good diagnostic marker for rheumatoid arthritis(136). However, 
whether this is the case for osteoarthritis and the potential involvement of PHOSPHO1 in this 
is yet to be established. 
8. Other physiological roles 
In the 20 years since its characterization, the vast majority of research focussing on 
PHOSPHO1 has concentrated on biomineralization. However, as a phosphatase capable of 
hydrolysing PCho and PEA with the generation of metabolites such as choline, PHOSPHO1 
has the potential for activity in many other body systems. PC and PE are two of the most 
abundant lipids in the body, comprising 40-50% and 15-20% respectively of total cellular 
phospholipids of any given tissue in mammals(137). These molecules are therefore of critical 
importance in a huge variety of biological systems, from the integrity of plasma membranes, 
and other structures such as vesicles, lipoproteins and chylomicrons, to regulating the activity 
of proteins at the cell membrane(137,138). Interestingly, the breakdown products from PC in 
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particular have also been implicated as signalling molecules(139,140). Although speculative, it 
is therefore an intriguing possibility that PHOSPHO1 may have a role to play in the 
biosynthesis and catalysis pathways of these phospholipids, regulating substrate availability. 
Choline is the breakdown product from PHOSPHO1 activity on the LPL 
lysophosphatidylcholine derived from PC, and is an essential dietary nutrient in mammals. 
Although choline is primarily used in PC biosynthesis, it may also be used to generate betaine 
in the liver and kidney, or acetylated to form the neurotransmitter acetylcholine in the 
brain(141). PHOSPHO1 may therefore be an appealing candidate to act within a secondary 
mechanism of choline homeostasis in these and other tissues. Indeed, gut enteroids 
maintained in choline-deficient media exhibited hypomethylation at 3’ CpG islands within 
the Phospho1 gene, potentially regulating gene expression(142). 
One system within which PHOSPHO1 plays a significant role in this regard is erythropoiesis. 
An expression quantitative trait locus (eQTL) analysis initially found that single nucleotide 
polymorphisms (SNPs) associated with β- thalassemia in human peripheral blood samples 
were also associated with changes in PHOSPHO1 expression(143). PHOSPHO1 was also 
found to be substantially enriched in erythroblasts undergoing differentiation(144). 
Subsequently Huang et al investigated PHOSPHO1 in terminal erythropoiesis; a process 
during which the phospholipid composition of red cells is substantially altered(145). 
PHOSPHO1 expression was significantly upregulated during erythroblast differentiation, and 
moreover loss of PHOSPHO1 induced defective erythropoiesis accompanied by a lack of 
choline generation and an increased phosphocholine:choline ratio. 
Several other studies have found intriguing associations between PHOSPHO1 expression and 
disorders of altered energy metabolism such as diabetes and obesity. Epigenome-wide 
association studies (EWAS) have found significant associations between methylation at loci 
within the PHOSPHO1 and the future risk of type-2 diabetes in human cohorts(146,147). 
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Indeed, Willmer and colleagues highlighted differential methylation at sites within the 
PHOSPHO1 gene as a potentially useful biomarker for clinical application in the early 
detection of type-2 diabetes(148). Moreover, increased methylation was positively correlated 
with high density lipoprotein (HDL) concentration in blood and was decreased in muscle 
tissue from diabetic patients(147). This relationship with HDL concentration was also 
reproduced independently in an EWAS focussed on serum lipid profiles conducted in a 
separate cohort(149). Relatedly, Wu et al further found an association between PHOSPHO1 
and SNPs relating to clinical measures of obesity in a Chinese population(150). These studies 
provide a promising avenue of investigation for future research to consider the mechanisms 
through which PHOSPHO1 may act to influence lipid metabolism and disorders of its 
dysregulation such as diabetes and obesity. Supporting this idea, changes in Phospho1 
expression have been found in several studies examining the thermogenic brown adipose 
tissue (BAT) and the browning of white adipose tissue (WAT), of great relevance to obesity. 
Phospho1 is expressed at a higher level in BAT than WAT(151), and suppression of fatty acid 
oxidation in adipose tissues causes a downregulation in expression during cold challenge(152). 
Furthermore, studies which have investigated creatine metabolism as an alternative pathway 
for thermogenesis in beige fat have implicated PHOSPHO1 in this process, although the 
specific mechanism remains elusive(153,154). 
9. Inhibition of PHOSPHO1 – a therapeutic target? 
The LOPAC and Spectrum chemical reference libraries were used to identify potential 
chemical inhibitors of PHOSPHO1 and semi-automated high-throughput chemical screening 
used to test inhibition of PEA hydrolysis(24). Of those identified, three molecules, 
Lansoprazole, Ebseleln and SCH202676 exhibited non-competitive inhibition of recombinant 
PHOSPHO1 activity by 80% or more(24). This study showed that neither Lansoprazole nor  
SCH202676 inhibited TNAP activity but Lansoprazole has recently been shown to act as a 
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non-competitive inhibitor of TNAP(155). Following this Bravo et al synthesized a series of 
benzoisothiazolone inhibitors of PHOSPHO1, the final selection from which was tested and 
passed medicinal chemistry criteria in deliverability, metabolic stability, solubility and 
permeability, whilst also demonstrating no cellular toxicity(156). 
The development of these compounds opens the potential for inhibition of PHOSPHO1 
activity as a therapeutic intervention. Although there has been no experimental research 
exploring this possibility to date, the imputation of PHOSPHO1’s association with 
pathologies in both biomineralization and lipid metabolism may make it an attractive drug 
target in the future. In terms of disorders of pathological mineralization, while the 
PHOSPHO1-mediated mineralization mechanism is critical for the proper development of the 
skeleton in immature organisms as has been discussed here, there is currently no evidence to 
suggest that it plays an active role in maintenance of the skeleton in adulthood. Ablation of 
mineralization in the adult may be desirable when attempting to control soft tissue 
mineralization e.g. vascular calcification and also ectopic bone formation as is the case in 
several musculoskeletal disorders including osteoarthritis. In these instances pharmacological 
inhibition of PHOSPHO1 may prove to represent an effective intervention which also entails 
limited adverse off-target effects. 
10. Outlook 
Over the past 20 years PHOSPHO1 has been an increasing focus of research in the bone 
biology and biomineralization communities. Work performed in our and in other groups has 
succeeded in establishing its canonical role in MV-mediated biomineralization of the skeleton 
and dentition, while opening new fields of investigation into its function in other body 
systems. Many questions remain to be answered surrounding aspects of PHOSPHO1’s 
biology, including detailed elucidation of its upstream biochemical mechanism, targeting of 
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the enzyme to MVs, how local and systemic regulation is integrated with other aspects of 
bone biology during the bone formation process, and the precise role of PHOSPHO1in 
musculoskeletal disease. Future studies integrating aspects of structural biology and 
biomineralization with cellular and molecular biology and endocrinology will give us a 
holistic appreciation of these processes and contribute to our understanding in this 
fundamental aspect of bone biology. 
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Figure 1: A) Goldner’s trichrome staining of wild-type and Phospho1-/- tibial sections 
demonstrating osteoid accumulation in the trabeculae bone (red staining; black arrowheads). 
Tibiae were dissected from 21 day-old C67BL/6 mice and fixed in 4% paraformaldehyde 
before decalcification in 10% EDTA in PBS and standard histological processing. 3µm 
sections were cut using a rotary microtome and used for staining. Scale bars represent 
200µm. B) Radiographic images of 1-year old Phospho1+/- and Phospho1-/- mice 
demonstrating thoracic scoliosis on ablation of Phospho1 (black arrowheads). Whole-body 
images were acquired using a MX20 Specimen Radiograph System (Faxitron, USA). Scale 
bars represent 20mm. 
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Figure 2: Optical projection tomography (OPT) reconstructions of mouse embryos at 17 days 
of gestation (E17) showing marked ablation of mineralization in bones of the skull in 
Phospho1-/- animals. E17 C67BL/6 wild-type and Phospho1-/- embryos were culled using 
Schedule 1 methods, fixed in 4% paraformaldehyde and whole mount stained in a 0.001% 
Alizarin Red solution in 1% potassium hydroxide. Samples were embedded in 1% agarose 
and scanned using a Bioptonics 3001 OPT Scanner (Bioptonics, UK). Data were 
reconstructed using NRecon (Bruker, USA) and visualised using Imaris (Bitplane, UK). Scale 
bars represent 10mm. 
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Figure 3: Schematic diagram illustrating the hypothesised mechanism of PHOSPHO1 
function within MVs. A) PHOSPHO1 functions synergistically with TNAP: 1] TNAP 
hydrolyses its substrates to produce Pi extravesicuarly; 2] Extravesicular Pi is transported into 
the MV via PiT1; 3] PHOSPHO1 hydrolyses Pcho intravesicuarly to further accumulate Pi. 
B) Generation of PHOSPHO1 substrates within MVs: 1] An unidentified PLA2 converts PC 
from the vesicle membrane to lysoPC; 2] NPP6 subsequently catalyses the hydrolysis of 
lysoPC to generate Pcho; 3] PHOSPHO1 liberates Pi from PCho. C) Alternative pathways of 
PCho generation: 1] nSmase2 breaks down SM from the MV membrane to form Pcho; 2] The 
α/β choline kinases phosphorylate choline to form PCho; 3] PHOSPHO1 generates Pi from 
PCho. 
 
 
